RecruitingNot ApplicableNCT05903170

Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation

A Randomised Trial of Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation


Sponsor

Wellington Hospital

Enrollment

100 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to compare the efficacy of a maximum output shock for cardioverting atrial fibrillation between two commonly used defibrillators in New Zealand . These machines have different maximum energy outputs, and to date no head-to-head comparison cardioverting atrial fibrillation between the two has been undertaken. The main question it aims to answer is whether either device is more likely to cardiovert patients referred for atrial fibrillation. Participants will be randomized to undergo cardioversion with one of two defibrillators at either 200J or 360J. Participants in each arm will undergo up to three shocks at the energy-level to which they have been randomized, using a standardized procedure. For participants randomized to the lower energy level who fail to return to normal rhythm after three shocks, they will be given a fourth shock at the higher energy level. All participants will then be asked to undertake a blood test the day following the cardioversion, and receive a follow up phone call. These are to ensure there is no difference in the safety of the procedure between the two energy levels. It is worth noting that these two components of the study (the blood test and phone call) are the only additional time commitment that is expected to be involved if you choose to participate in the study.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing different shock energy levels used during electrical cardioversion — a procedure that uses a brief electric shock to reset an irregular heartbeat back to normal rhythm — to determine which energy level is most effective for atrial fibrillation. **You may be eligible if...** - You are over 18 years old - You are scheduled for elective or non-emergency cardioversion for atrial fibrillation - You are eligible for and have been reliably on blood thinners for at least 3 weeks, or your atrial fibrillation started within the past 48 hours, or a heart scan has ruled out a clot - You are able to consent to both cardioversion and study participation **You may NOT be eligible if...** - You have atrial flutter (a related but different rhythm problem) - This is an emergency cardioversion - You have a pacemaker or implantable defibrillator - You are pregnant - You cannot consent to participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE360J LifePak Monitor/Defibrillator

The LifePak Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 360J.

DEVICE200J Philips HeartStart MRx Monitor/Defibrillator

The Philips HeartStart MRx Monitor/Defibrillator is a commonly-used defibrillator in New Zealand hospitals for cardioverting atrial fibrillation. It delivers a biphasic waveform shock with a titratable maximum energy of 200J.


Locations(1)

Wellington Regional Hospital

Wellington, Wellington Region, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05903170


Related Trials